Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ELA026 Following Intravenous and/or Subcutaneous Administration of Single and Multiple Doses in Healthy Adults

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ELA026 Following Intravenous and/or Subcutaneous Administration of Single and Multiple Doses in Healthy Adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELA 026 (Primary) ; ELA 026 (Primary)
  • Indications Haemophagocytic lymphohistiocytosis; Immunological disorders
  • Focus Adverse reactions
  • Sponsors Electra Therapeutics

Most Recent Events

  • 22 Oct 2025 Results presented in the Electra Therapeutics media release.
  • 22 Oct 2025 According to an Electra Therapeutics Inc media release, based on positive results from this Phase 1b study ELA026 received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation (BTD) and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH).
  • 26 Mar 2024 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top